T. Rowe Price Associates
RLMD icon

T. Rowe Price Associates’s Relmada Therapeutics RLMD Stock Holding History

T. Rowe Price Associates’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-159,290
Closed -$478K – 2923
2023
Q3 		$478K Sell
159,290
-3,146
-2% -$9.35K ﹤0.01% 2124
2023
Q2 		$400K Sell
162,436
-16,004
-9% -$44.2K ﹤0.01% 2235
2023
Q1 		$404K Sell
178,440
-9,019
-5% -$31.1K ﹤0.01% 2198
2022
Q4 		$654K Sell
187,459
-9,097
-5% -$79.9K ﹤0.01% 2004
2022
Q3 		$7.28M Buy
196,556
+27,799
+16% +$770K ﹤0.01% 1125
2022
Q2 		$3.21M Buy
168,757
+11,192
+7% +$244K ﹤0.01% 1491
2022
Q1 		$4.25M Buy
+157,565
New +$3.26M ﹤0.01% 1493
2021
Q4 		– Sell
-8,057
Closed -$211K – 3031
2021
Q3 		$211K Buy
+8,057
New +$216K ﹤0.01% 2703
2020
Q1 		– Sell
-129,461
Closed -$5.05M – 2551
2019
Q4 		$5.05M Buy
+129,461
New +$3.93M ﹤0.01% 1393

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

T. Rowe Price Associates's RLMD Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 159,290 shares — an estimated $478K sold.

T. Rowe Price Associates first reported a position in RLMD in Q4 2019 and held it in 9 quarters. The position peaked at $7.28M in Q3 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • T. Rowe Price Associates reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 159,290 Relmada Therapeutics shares in Q4 2023, an estimated $478K.
  • T. Rowe Price Associates first reported a position in Relmada Therapeutics in Q4 2019 and held it in 9 quarters.
  • T. Rowe Price Associates's Relmada Therapeutics position peaked at $7.28M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.